Why blinding is difficult in psychedelic trials

Takeaway

One-sentence takeaway: Published high-dose psychedelic trials report functional unblinding exceeding 90%, while single-dose research in healthy adults has evaluated low-dose oral psilocybin to characterize perceptual thresholds; whether blinding holds during repeated sub-perceptual XYCO-02 dosing in adults with mild PTSD remains an open question.

1. Published observations: the gold standard under strain

The double-blind, randomized, placebo-controlled trial (RCT) has been the standard for evaluating candidate medicines for more than seventy years. When neither the participant nor the investigator knows whether an active substance or an inert comparator was given, symptom changes can be separated from expectation. In high-dose psychedelic trials, however, that blind is frequently compromised (Muthukumaraswamy et al., Expert Rev Clin Pharmacol 2021).

2. The mechanics of functional unblinding

When a participant in a clinical trial receives a perceptible dose (for example, 25 mg of psilocybin in a supervised session), perceptual changes, affective shifts, and somatic effects typically appear within an hour (Goodwin et al., NEJM 2022). Published reviews report functional unblinding exceeding 90% in macrodose studies (Muthukumaraswamy et al., 2021). That creates a structural challenge in both arms:

Active arm

Participants who notice acute psychedelic effects can infer they received the active drug, which may amplify positive expectancy.

Inert placebo arm

Participants who notice no perceptual change may infer they received placebo, which can introduce disappointment on self-reported symptom scales.

↓ Expectancy differences between arms complicate interpretation of double-blind efficacy readouts

Regulatory guidance on expectancy and unblinding

In June 2023 the U.S. FDA issued guidance, Psychedelic Drugs: Considerations for Clinical Investigations (finalized in 2026), identifying functional unblinding and expectancy bias as key methodological considerations in psychedelic clinical trials. If participants can tell which treatment they received, it is harder to interpret a trial.

3. Xycota's dosing goal and published single-dose evidence on low-dose thresholds

In a 2026 rat study (Ascone et al., Neuropsychopharmacology 2026), repeated low doses of psilocybin improved object-recognition memory in a Fragile X rat model; the improvement remained when researchers blocked 5-HT2A and disappeared when they blocked TrkB (see our companion article on BDNF/TrkB signaling). That animal finding motivates Xycota's investigation of low-dose psilocybin in people.

What "sub-perceptual" means. Sub-perceptual describes the design goal for XYCO-02. The low-dose oral regimen is formulated to stay below the threshold of noticeable psychedelic effects. Whether participants with mild PTSD can distinguish XYCO-02 from placebo during repeated dosing remains an open question.
Published single-dose human evidence. A blinded single-dose study in healthy adults evaluated low-dose oral psilocybin across minimal milligram doses to characterize perceptual thresholds relative to placebo (read the single-dose study in healthy adults). Whether blinding holds with repeated XYCO-02 dosing in people with mild PTSD remains unknown.
Planned study readouts. The planned 28-day double-blind study will assess changes in PTSD symptoms using CAPS-5 and measure BDNF levels in blood. A change in blood BDNF alone would not establish brain repair or receptor engagement.

Investigational status. XYCO-02 is preclinical and not approved. Double-blind describes the planned study design; whether blinding holds during repeated dosing and whether participants experience a change in PTSD symptoms remain open questions to be tested.

4. Supervised clinic sessions vs. planned at-home study

Alongside functional unblinding, high-dose psychedelic protocols require 25 mg administration in a supervised clinic session lasting 6 to 8 hours (Goodwin et al., NEJM 2022). Full-day in-clinic sessions create a practical participation barrier for many outpatient populations.

XYCO-02 is a sub-perceptual oral capsule being prepared for a planned 28-day double-blind at-home study in adults with mild PTSD. Whether an outpatient low-dose regimen is safe and effective in people has not yet been established and depends on future clinical trials and regulatory review.

5. Conclusion

Functional unblinding exceeding 90% and 6- to 8-hour supervised clinic sessions are documented constraints of high-dose psychedelic protocols. By formulating a sub-perceptual dose intended to minimize noticeable psychedelic effects, Xycota plans to evaluate XYCO-02 in a 28-day double-blind at-home study in adults with mild PTSD. Both symptom change and repeated-dose blinding in mild PTSD remain to be tested.

To review clinical trial designs, investigator materials, or partnership opportunities, qualified investors and partners can request access to the Xycota data room.

References

U.S. Food & Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry. Draft June 2023; finalized 2026.
Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology. 2021;14(9):1133-1152. doi:10.1080/17512433.2021.1933434.
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443.
Ascone F, Buzzelli V, Mottarlini F, et al. Neuropsychopharmacology (2026), 51(8):1454-1463. doi:10.1038/s41386-026-02361-x.
Levy-Cooperman N, et al. Single-ascending-dose study of oral psilocybin in healthy adults. Pharmaceuticals. 2026. PMID: 42797541.

functional unblindingpsychedelic trial designFDA guidanceHealth Canada CTAPTSD endpointssub-perceptual dosing

View the Pipeline All Insights